Finoriq research workspace
Aditxt, Inc. (ADTX) SEC Filings & Filing Highlights
Aditxt, Inc. develops AditxtScore and FlowSpot that enable individuals to understand, manage. Review ADTX SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Aditxt, Inc. focuses on discovery and development of biopharmaceutical products. The company develops AditxtScore and FlowSpot that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It develops ADI-100 for skin grafting, psoriasis, and type-1 diabetes. In addition, the company provides Pearsanta that develops molecular tests based on the mitochondrial DNA (mtDNA) to develop tests for early detection of cancer; Mitomic targets mutations in mitochondrial DNA (mtDNA) to detect disease; Mitomic prostate test a blood-based assay that quantifies the level of the 3.4kb mtDNA deletion; and Mitomic endometriosis test, a blood-based assay that quantifies the level of one or more mtDNA deletions. Further, it offers Adivir for commercial development of products to address significant unmet needs in infectious disease and population health; and Adifem address critical unmet needs in women health. The company has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.
- Company
- Aditxt, Inc. (ADTX)
- Ticker
- ADTX
- Market Cap
- $7,833
- Latest Price
- $0.0096
- Industry
- Biotech & Pharma
Aditxt, Inc. (ADTX) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Aditxt, Inc. (ADTX).
| Event | Form | Date |
|---|---|---|
| The Company may request that Nasdaq Listing and Hearing Review Council review the decision of t...On May 6, 2026. as previously reported in a Current Report on Form 8-K filed by Aditxt, Inc. (the “Company”) on May 8, 2026, the Company re... | 8-K3.01 | 2026-06-24 |
| On June 22, 2026, there were 997,976,543 shares of the Company’s common stock, par value $0.001...On June 22, 2026, there were 997,976,543 shares of the Company’s common stock, par value $0.001 per share, issued and outstanding | 8-K7.01 | 2026-06-23 |
| Aditxt, Inc.: Securities issuanceBased in part upon the representations of the Investors in the Purchase Agreement, the offer and sale of the Additional Notes by the Compan... | 8-K3.02 | 2026-06-23 |
| Aditxt, Inc.: Material agreementOn June 22, 2026, Aditxt, Inc. (the “Company”) entered into Amendment No.1 to Note Purchase Agreement (the “Amendment”) by and among the Co... | 8-K1.01 | 2026-06-23 |
| Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 MillionAditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million | 8-K7.01 | 2026-06-10 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.